Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 7/20 | 0.37 |
| ▸ | MMP1 | P03956 | 6/20 | 0.37 |
| ▸ | MMP13 | P45452 | 6/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793873 | 1.00 | ADAM17 (0.37) | ADAM17MMP1MMP13ADAMTS4ADAMTS5 | |
| SCHEMBL5201960 | 0.89 | MEN1 (0.40) | ADAM17MMP1MMP13ADAMTS4ADAMTS5 | |
| SCHEMBL5201963 | 0.89 | MEN1 (0.40) | ADAM17MMP1MMP13ADAMTS4ADAMTS5 | |
| SCHEMBL5200884 | 0.86 | CNR1 (0.41) | CNR1ITGB1ITGA4SLC13A5AKR1C3 | |
| SCHEMBL5200881 | 0.86 | CNR1 (0.41) | CNR1ITGB1ITGA4SLC13A5AKR1C3 | |
| SCHEMBL5201586 | 0.86 | CNR1 (0.41) | CNR1ITGB1ITGA4SLC13A5AKR1C3 | |
| SCHEMBL5201582 | 0.86 | CNR1 (0.41) | CNR1ITGB1ITGA4SLC13A5AKR1C3 | |
| SCHEMBL21540493 | 0.78 | ITGB1 (0.49) | MMP1MMP13CNR1ITGB1ITGA4 | |
| SCHEMBL5201579 | 0.75 | MEN1 (0.49) | HCRTR1HCRTR2AKR1C3 | |
| SCHEMBL5201573 | 0.75 | MEN1 (0.49) | HCRTR1HCRTR2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ICAM1 | ADAM17 950/4885MMP1 275/4885MMP13 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.